A Safety Study of Mebendazole in Children 2 to 10 Years of Age
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of mebendazole 500-mg
chewable tablet formulation in a pediatric population. Mebendazole is a drug used for the
treatment of soil-transmitted parasitic helminth (STH) (ie, parasitic worm) infections such
as pinworm, whipworm, common roundworm, common hookworm, and American hookworm.
Phase:
Phase 3
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.